Results for tag: "ALKS 8700"

The ALKS 8700 is a central nervous system (CNS) drug developed by Alkermes plc. It is an oral, once-daily, extended-release formulation of buprenorphine and samidorphan, two drugs that have been used to treat opioid use disorder (OUD). ALKS 8700 is designed to reduce the risk of misuse and abuse associated with buprenorphine and samidorphan. It is also being studied for the treatment of major depressive disorder (MDD). The CNS drug market is a rapidly growing sector of the pharmaceutical industry. It includes drugs used to treat a wide range of neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, schizophrenia, and depression. The market is expected to continue to grow as new treatments are developed and existing treatments are improved. Some of the major companies in the CNS drug market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Other companies, such as Alkermes plc, are also developing new treatments for CNS disorders. Show Less Read more